Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 2.48 1.22% 0.03
RIGL closed up 1.22 percent on Monday, March 25, 2019, on 66 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical RIGL trend table...

Date Alert Name Type % Chg
Mar 25 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 25 Upper Bollinger Band Walk Strength 0.00%
Mar 25 Overbought Stochastic Strength 0.00%
Mar 22 Upper Bollinger Band Walk Strength 1.22%
Mar 22 Overbought Stochastic Strength 1.22%
Mar 22 Upper Bollinger Band Touch Strength 1.22%
Mar 21 180 Bullish Setup Bullish Swing Setup -6.42%
Mar 21 Pocket Pivot Bullish Swing Setup -6.42%
Mar 21 Upper Bollinger Band Walk Strength -6.42%
Mar 21 Above Upper BB Strength -6.42%

Older signals for RIGL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Cancer Chemical Compounds Rheumatoid Arthritis Asthma Drug Development Enzymes Tyrosine Kinase Inhibitors Inflammatory And Autoimmune Diseases Tyrosine Kinase Janus Kinase Portola Pharmaceuticals Tyrosine Kinases
Is RIGL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.68
52 Week Low 1.96
Average Volume 1,989,645
200-Day Moving Average 2.7517
50-Day Moving Average 2.261
20-Day Moving Average 2.348
10-Day Moving Average 2.467
Average True Range 0.129
ADX 20.11
+DI 23.8043
-DI 17.3273
Chandelier Exit (Long, 3 ATRs ) 2.293
Chandelier Exit (Short, 3 ATRs ) 2.387
Upper Bollinger Band 2.649
Lower Bollinger Band 2.047
Percent B (%b) 0.72
BandWidth 25.638842
MACD Line 0.0726
MACD Signal Line 0.052
MACD Histogram 0.0205
Fundamentals Value
Market Cap 308.49 Million
Num Shares 124 Million
EPS -0.68
Price-to-Earnings (P/E) Ratio -3.65
Price-to-Sales 45.70
Price-to-Book 6.79
PEG Ratio -0.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.65
Resistance 3 (R3) 2.64 2.58 2.62
Resistance 2 (R2) 2.58 2.54 2.58 2.61
Resistance 1 (R1) 2.53 2.51 2.56 2.54 2.60
Pivot Point 2.47 2.47 2.48 2.47 2.47
Support 1 (S1) 2.42 2.43 2.45 2.43 2.36
Support 2 (S2) 2.36 2.40 2.36 2.35
Support 3 (S3) 2.31 2.36 2.34
Support 4 (S4) 2.32